The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study

Journal of Cardiovascular Pharmacology and Therapeutics
Teruhiko MatsushimaMEGA Study Group

Abstract

The Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study demonstrated the beneficial effect of low-dose pravastatin treatment (10-20 mg/d) on cardiovascular disease (CVD) in Japanese patients with mild-to-moderate hypercholesterolemia. However, it is not known whether mild lipid modification is effective even for patients at high risk. In this study, we evaluated low-dose pravastatin treatment in patients with metabolic syndrome in the MEGA Study. Metabolic syndrome (MetSyn) was defined according to the modified US National Cholesterol Education Program criteria. There were 72 coronary heart disease (CHD) events and 130 CVD events in 2636 patients with MetSyn, and 70 CHD events and 125 CVD events in 5196 patients without MetSyn (hazard ratios 1.85 and 1.90, respectively). No significant risk reduction in CHD was found in the diet plus pravastatin group compared with the diet group patients with MetSyn (hazard ratio .78, P = .29). On the other hand, there was a significant 36% CVD risk reduction (P = .01) in the diet plus pravastatin group compared with the diet group patients with MetSyn, with a small number needed to treat (45). These results indicate that low-dose pravastatin provi...Continue Reading

References

Aug 27, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·UNKNOWN Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group
Sep 27, 2005·Lancet·K George M M AlbertiUNKNOWN IDF Epidemiology Task Force Consensus Group
Dec 30, 2006·Circulation·Wayne RosamondUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Feb 21, 2007·Circulation·Lori MoscaUNKNOWN American College of Nurse Practitioners

❮ Previous
Next ❯

Citations

Nov 23, 2013·Cancer Causes & Control : CCC·Yanqiong LiuXue Qin
Dec 10, 2013·The Journal of Veterinary Medical Science·Shinji AritaYoshiaki Hikasa
Dec 15, 2015·Trends in Cardiovascular Medicine·Scott M Grundy

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Clinical Trials Mentioned

NCT00211705

Related Concepts

Related Feeds

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.